Regeneron Gets FDA Fast-Track Status for Treatment of Rare Inflammation Disorders TARRYTOWN, N.Y. (AP) -- Biotech drug maker Regeneron Pharmaceuticals Inc. said Wednesday the Food and Drug Administration gave its chronic inflammation treatment a fast-track designation.

The fast-track status allows a company to submit clinical trial data to the FDA as it becomes available, and receive feedback, rather than having to wait to submit all data at once.

The company is running a late-stage clinical trial for its IL-1 Trap, a compound designed to attach to and neutralize a certain protein that causes inflammation when in excess. The trial is testing the treatment in patients with CIAS1-Associated Periodic Syndromes, a collection of rare genetic disorders that result in chronic inflammation.

Regeneron said it hopes to start releasing data from the trial by the end of the year. The drug was previously given orphan drug status by the FDA, a designation granted to pharmaceuticals that treat diseases affecting fewer than 200,000 people in the U.S.